385 related articles for article (PubMed ID: 23197570)
1. Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.
Foltz IN; Hu S; King C; Wu X; Yang C; Wang W; Weiszmann J; Stevens J; Chen JS; Nuanmanee N; Gupte J; Komorowski R; Sekirov L; Hager T; Arora T; Ge H; Baribault H; Wang F; Sheng J; Karow M; Wang M; Luo Y; McKeehan W; Wang Z; Véniant MM; Li Y
Sci Transl Med; 2012 Nov; 4(162):162ra153. PubMed ID: 23197570
[TBL] [Abstract][Full Text] [Related]
2. Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.
Kolumam G; Chen MZ; Tong R; Zavala-Solorio J; Kates L; van Bruggen N; Ross J; Wyatt SK; Gandham VD; Carano RA; Dunshee DR; Wu AL; Haley B; Anderson K; Warming S; Rairdan XY; Lewin-Koh N; Zhang Y; Gutierrez J; Baruch A; Gelzleichter TR; Stevens D; Rajan S; Bainbridge TW; Vernes JM; Meng YG; Ziai J; Soriano RH; Brauer MJ; Chen Y; Stawicki S; Kim HS; Comps-Agrar L; Luis E; Spiess C; Wu Y; Ernst JA; McGuinness OP; Peterson AS; Sonoda J
EBioMedicine; 2015 Jul; 2(7):730-43. PubMed ID: 26288846
[TBL] [Abstract][Full Text] [Related]
3. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c.
Suzuki M; Uehara Y; Motomura-Matsuzaka K; Oki J; Koyama Y; Kimura M; Asada M; Komi-Kuramochi A; Oka S; Imamura T
Mol Endocrinol; 2008 Apr; 22(4):1006-14. PubMed ID: 18187602
[TBL] [Abstract][Full Text] [Related]
4. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein.
Smith R; Duguay A; Bakker A; Li P; Weiszmann J; Thomas MR; Alba BM; Wu X; Gupte J; Yang L; Stevens J; Hamburger A; Smith S; Chen J; Komorowski R; Moore KW; Véniant MM; Li Y
PLoS One; 2013; 8(4):e61432. PubMed ID: 23630589
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals.
Rajan S; Mandikian D; Baruch A; Gelzleichter TR; Stevens D; Sonoda J; Cowan K; Boswell CA; Stefanich E
MAbs; 2017; 9(8):1379-1388. PubMed ID: 28895785
[TBL] [Abstract][Full Text] [Related]
6. FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes.
Chen MZ; Chang JC; Zavala-Solorio J; Kates L; Thai M; Ogasawara A; Bai X; Flanagan S; Nunez V; Phamluong K; Ziai J; Newman R; Warming S; Kolumam G; Sonoda J
Mol Metab; 2017 Nov; 6(11):1454-1467. PubMed ID: 29107292
[TBL] [Abstract][Full Text] [Related]
7. A unique FGF23 with the ability to activate FGFR signaling through both αKlotho and βKlotho.
Wu X; Weiszmann J; Ge H; Baribault H; Stevens J; Hawkins N; Vonderfecht S; Gardner J; Gupte J; Sheng J; Wang M; Li Y
J Mol Biol; 2012 Apr; 418(1-2):82-9. PubMed ID: 22370560
[TBL] [Abstract][Full Text] [Related]
8. FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.
Ye M; Lu W; Wang X; Wang C; Abbruzzese JL; Liang G; Li X; Luo Y
Endocrinology; 2016 Dec; 157(12):4754-4769. PubMed ID: 27690692
[TBL] [Abstract][Full Text] [Related]
9. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases.
Sonoda J; Chen MZ; Baruch A
Horm Mol Biol Clin Investig; 2017 May; 30(2):. PubMed ID: 28525362
[TBL] [Abstract][Full Text] [Related]
10. FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia.
Lan T; Morgan DA; Rahmouni K; Sonoda J; Fu X; Burgess SC; Holland WL; Kliewer SA; Mangelsdorf DJ
Cell Metab; 2017 Nov; 26(5):709-718.e3. PubMed ID: 28988823
[TBL] [Abstract][Full Text] [Related]
11. Discovery of an artificial peptide agonist to the fibroblast growth factor receptor 1c/βKlotho complex from random peptide T7 phage display.
Sakamoto K; Kawata Y; Masuda Y; Umemoto T; Ito T; Asami T; Takekawa S; Ohtaki T; Inooka H
Biochem Biophys Res Commun; 2016 Nov; 480(1):55-60. PubMed ID: 27717820
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans.
Baruch A; Wong C; Chinn LW; Vaze A; Sonoda J; Gelzleichter T; Chen S; Lewin-Koh N; Morrow L; Dheerendra S; Boismenu R; Gutierrez J; Wakshull E; Wilson ME; Arora PS
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28992-29000. PubMed ID: 33139537
[TBL] [Abstract][Full Text] [Related]
13. Interactions Between the Gravitostat and the Fibroblast Growth Factor System for the Regulation of Body Weight.
Palsdottir V; Windahl SH; Hägg DA; Keantar H; Bellman J; Buchanan A; Vaughan TJ; Lindén D; Jansson JO; Ohlsson C
Endocrinology; 2019 May; 160(5):1057-1064. PubMed ID: 30888399
[TBL] [Abstract][Full Text] [Related]
14. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism.
Ge H; Baribault H; Vonderfecht S; Lemon B; Weiszmann J; Gardner J; Lee KJ; Gupte J; Mookherjee P; Wang M; Sheng J; Wu X; Li Y
PLoS One; 2012; 7(3):e33603. PubMed ID: 22457778
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.
Wu AL; Kolumam G; Stawicki S; Chen Y; Li J; Zavala-Solorio J; Phamluong K; Feng B; Li L; Marsters S; Kates L; van Bruggen N; Leabman M; Wong A; West D; Stern H; Luis E; Kim HS; Yansura D; Peterson AS; Filvaroff E; Wu Y; Sonoda J
Sci Transl Med; 2011 Dec; 3(113):113ra126. PubMed ID: 22174314
[TBL] [Abstract][Full Text] [Related]
17. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
[TBL] [Abstract][Full Text] [Related]
18. Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases.
Zhao L; Niu J; Lin H; Zhao J; Liu Y; Song Z; Xiang C; Wang X; Yang Y; Li X; Mohammadi M; Huang Z
EBioMedicine; 2019 Oct; 48():462-477. PubMed ID: 31631034
[TBL] [Abstract][Full Text] [Related]
19. Agonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions.
Min X; Weiszmann J; Johnstone S; Wang W; Yu X; Romanow W; Thibault S; Li Y; Wang Z
J Biol Chem; 2018 Sep; 293(38):14678-14688. PubMed ID: 30068552
[TBL] [Abstract][Full Text] [Related]
20. Peptide-Based Regulation of Metabolism as Related to Obesity.
Bergen WG
Endocrinology; 2017 Oct; 158(10):3081-3082. PubMed ID: 28977611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
